TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN Share Price
Certificat
DE000SD4L9W8
| Market Closed - Boerse Frankfurt Warrants 01:13:51 26/06/2024 am IST | ||
| 8.89 EUR | +3.61% |
|
| Current month | +18.46% | ||
| 1 month | +15.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 8.92 | +3.96% |
| 24/24/24 | 8.58 | +6.85% |
| 21/24/21 | 8.03 | +1.26% |
| 20/24/20 | 7.93 | +5.03% |
| 19/24/19 | 7.55 | -0.40% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SD4L9W |
| ISIN | DE000SD4L9W8 |
| Date issued | 12/03/2021 |
| Strike | 226.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.09 € |
|---|---|
| Lowest since issue | 0.61 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319.3
USD
Average target price
316.4
USD
Spread / Average Target
-0.90%
- Stock Market
- Certificates
- Certificat
